IRWD - Ironwood Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.86
-0.11 (-1.28%)
As of 1:33PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close8.98
Open8.90
Bid8.86 x 1000
Ask8.87 x 900
Day's Range8.79 - 9.19
52 Week Range7.60 - 16.45
Volume250,994
Avg. Volume1,566,314
Market Cap1.387B
Beta (3Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.63
Trade prices are not sourced from all markets
  • Business Wire

    Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment

    Ironwood Pharmaceuticals, Inc. (“Ironwood”) (IRWD), a GI-focused healthcare company, today announced that, in connection with its previously announced offering of 0.75% Convertible Senior Notes due 2024 (the “2024 Notes”) and 1.50% Convertible Senior Notes due 2026 (the “2026 Notes” and, together with the 2024 Notes, the “Notes”), the initial purchaser exercised in full its option to purchase $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes (the “Additional Notes”). Ironwood estimates that the net proceeds of the offering will be approximately $390 million (including the previously announced net proceeds of approximately $341 million from the initial closing of the offering of Notes, which occurred on August 12, 2019) after deducting the initial purchaser’s discounts and commissions, but prior to deducting estimated offering expenses.

  • Business Wire

    Alnylam Pharmaceuticals and Ironwood Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare company, announced today a U.S. GI disease education and promotional agreement for Alnylam’s givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the potential treatment of AHP. Givosiran has received Priority Review designation and Breakthrough Therapy Designation from the U.S. FDA, as well as Orphan Drug Designation in the U.S. The Prescription Drug User Fee Act (PDUFA) date for givosiran is set for February 4, 2020.

  • Business Wire

    Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)

    Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare company, announced today a U.S. GI disease education and promotional agreement for Alnylam’s givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the potential treatment of AHP. Givosiran has received Priority Review designation and Breakthrough Therapy Designation from the U.S. FDA, as well as Orphan Drug Designation in the U.S. The Prescription Drug User Fee Act (PDUFA) date for givosiran is set for February 4, 2020.

  • Business Wire

    Ironwood Pharmaceuticals Announces Pricing of Upsized $350 Million Convertible Senior Notes Offering

    Ironwood Pharmaceuticals, Inc. (“Ironwood”) (IRWD), a GI-focused healthcare company, today announced the pricing of $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 (the “2024 Notes”) and $175 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026 (the “2026 Notes” and, together with the 2024 Notes, the “Notes”). Ironwood has also granted the initial purchaser of the Notes an option to purchase, within a 13-day period from, and including, the date of original issuance of the Notes up to an additional $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes. The Notes will be convertible, only during certain periods and subject to certain circumstances, into cash, shares of Ironwood Class A common stock (“Ironwood common stock”), or a combination of cash and shares of Ironwood common stock, at Ironwood’s election.

  • Business Wire

    Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes

    Ironwood Pharmaceuticals, Inc. (“Ironwood”) (IRWD), a GI-focused healthcare company, today announced that it intends to offer, subject to market and other conditions, $165 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2024 (the “2024 Notes”) and $165 million aggregate principal amount of convertible senior unsecured notes that will mature on June 15, 2026 (the “2026 Notes” and, together with the 2024 Notes, the “Notes”). Ironwood also expects to grant the initial purchaser of the Notes an option to purchase, within a 13-day period from, and including, the date of original issuance of the Notes up to an additional $25 million aggregate principal amount of the 2024 Notes and $25 million aggregate principal amount of the 2026 Notes.

  • Thomson Reuters StreetEvents

    Edited Transcript of IRWD earnings conference call or presentation 30-Jul-19 8:30pm GMT

    Q2 2019 Ironwood Pharmaceuticals Inc Earnings Call

  • Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Ironwood (IRWD) Q2 Earnings and Revenues Beat Estimates

    Ironwood (IRWD) beats on earnings and sales in the second quarter. Demand for Linzess remains strong.

  • Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know
    Motley Fool

    Ironwood Pharmaceuticals' Blowout Q2 Results: What You'll Want to Know

    The drugmaker delivered its first-ever quarterly profit and trounced Wall Street top- and bottom-line estimates.

  • Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript
    Motley Fool

    Ironwood Pharmaceuticals Inc (IRWD) Q2 2019 Earnings Call Transcript

    IRWD earnings call for the period ending June 30, 2019.

  • Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates
    Zacks

    Ironwood Pharmaceuticals (IRWD) Q2 Earnings and Revenues Top Estimates

    Ironwood (IRWD) delivered earnings and revenue surprises of 214.29% and 12.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Ironwood Pharmaceuticals Reports Second Quarter 2019 Results

    – Generated $12 million in GAAP net income from continuing operations and $26 million in adjusted EBITDA from continuing operations in 2Q 2019 –

  • Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
    Zacks

    Ironwood Pharmaceuticals (IRWD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

    Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Should You Be Concerned About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Historical Volatility?

    If you're interested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), then you might want to consider its beta (a...

  • Business Wire

    Ironwood Pharmaceuticals to Host Second Quarter 2019 Investor Update Call

    Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its second quarter 2019 investor update conference call and webcast at 4:30 p.m. Eastern Time on Tuesday, July 30, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 1896718. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

  • 100 Summer lands WeWork ahead of tower's possible sale
    American City Business Journals

    100 Summer lands WeWork ahead of tower's possible sale

    Co-working giant WeWork is leasing yet another office in Boston, this time a 117,000-square-foot, three-floor spot at 100 Summer St. WeWork will house 2,300 desks at the tower, which Blackstone owns through its EQ Office arm.

  • Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)

    While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, increasing oil prices and optimism towards the resolution of the trade war with China, many smart money investors kept their cautious approach regarding the current bull run in the first quarter and hedging or reducing many of their […]

  • Company News For Jun 20, 2019
    Zacks

    Company News For Jun 20, 2019

    Companies In The News Are: VIAB,CBS,ADBE,X,AGN,IRWD

  • Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients
    Zacks

    Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients

    Ironwood (IRWD) and Allergan's Linzess meets the goal in a late-stage study for treating adult patients with IBS-C. Shares rise as the drug reduces bloating, pain and discomfort in IBS-C patients.

  • Benzinga

    Ironwood, Allergan Investors React Positively After Duo's Constipation Drug Found Effective

    Ironwood and Allergan plc (NYSE: AGN) announced positive topline results from a Phase 3b study evaluating Linzess 290 mcg for multiple abdominal symptoms in adult patients with irritable bowel syndrome with constipation, or IBS-C. The companies said the late-stage study met the primary multicomponent endpoint of the drug, when administered orally once-daily, demonstrating an improvement in overall abdominal symptoms of bloating, pain and discomfort in adult patients with IBS-C compared to placebo. Linzess, an FDA-approved drug for IBS-C or chronic idiopathic constipation, or IDC, is marketed in the U.S. by Ironwood and Allergan.

  • Business Wire

    Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

    Ironwood Pharmaceuticals, Inc. (IRWD) and Allergan plc (AGN) today announced positive topline data from a Phase IIIb clinical trial evaluating LINZESS (linaclotide) 290 mcg on multiple abdominal symptoms in adult patients with IBS-C. The trial met its primary multi-component endpoint and demonstrated that linaclotide improved the overall abdominal symptoms of bloating, pain and discomfort in adult IBS-C patients compared to placebo. The trial also met both secondary endpoints.

  • Markit

    See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.

    Ironwood Pharmaceuticals Inc NASDAQ/NGS:IRWDView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for IRWD with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding IRWD are favorable, with net inflows of $2.26 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Cambridge’s Ironwood Pharma moving HQ to downtown Boston
    American City Business Journals

    Cambridge’s Ironwood Pharma moving HQ to downtown Boston

    The move comes after longtime Ironwood CEO Peter Hecht left the company to lead spinoff Cyclerion Therapeutics.

  • Business Wire

    Ironwood Pharmaceuticals to Establish New Headquarters in Downtown Boston

    Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that the company plans to relocate its headquarters to a new office in downtown Boston from its current location in Cambridge, Massachusetts. Ironwood’s new headquarters will occupy approximately 39,000 square feet at 100 Summer Street. Ironwood anticipates the move to be completed in the fourth quarter of 2019, and expects to save more than $25 million in cash payments to its landlord over the following five years.